---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335073"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2026-08-05T20:07:47+00:00"
generated_at: "2026-08-05T20:10:40.145031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion Q2 net loss $8.3M, cash $35.2M; T1D C-peptide data positive

## Summary
- Net loss of $8.3M for Q2 2026, down from $20.7M in Q2 2025; cash $35.2M as of June 30, 2026.
- Cash runway projected into Q2 2027.
- Phase II COVALENT-211 (T2D insulin-deficient) data expected Q1 2027; COVALENT-212 (T2D on GLP-1 RA) data expected Q2 2027.
- Phase I GLP-131 (BMF-650 obesity) initial 28-day weight reduction data expected Q3 2026.
- T1D data: 52% increase in mean C-peptide AUC at Week 12 with icovamenib 200 mg; planning Phase II trial.

## SEC filing metadata
- accession: 0001193125-26-335073
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2026-08-05T20:07:47+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312526335073/0001193125-26-335073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312526335073/bmea-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335073
- JSON: https://secwatch.observer/filing/0001193125-26-335073.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.